Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389478 | 0.93 | CNR2 (0.39) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4396284 | 0.87 | CNR2 (0.40) | CNR2RECQLSMN1; SMN2TSHRGAA | |
| SCHEMBL4387546 | 0.86 | HPGD (0.42) | RECQLTSHRCYP2C19CYP2D6SLC6A2 | |
| SCHEMBL4387022 | 0.86 | CNR2 (0.44) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4395152 | 0.84 | CNR2 (0.40) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4391973 | 0.81 | CNR2 (0.39) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4377955 | 0.80 | CNR2 (0.38) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4391979 | 0.79 | EGFR (0.35) | RECQLSMN1; SMN2HDAC1HDAC2TSHR | |
| SCHEMBL4378125 | 0.79 | CNR2 (0.43) | CNR2RECQLPOLBSMN1; SMN2ESR1 | |
| SCHEMBL4381573 | 0.78 | CNR2 (0.37) | CNR2RECQLPOLBSMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262975-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Breye Therapeutics ApS (DK) | 2023-10-25 | — | — | EP | disclosed |
| EP-4110784-A1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022129365-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3710428-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3303323-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196513-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016100349-A2 | BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-06-23 | — | — | WO | disclosed |
| EP-2925745-A1 | CXCR7 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| WO-2009064418-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | CNR2 1898/4885RECQL 1489/4885POLB 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.